The first once-daily inhaled corticosteroid/long acting beta2-agonist combination has been launched in the UK for treating asthma and chronic obstructive pulmonary disease.
Fluticasone furoate/vilanterol (Relvar Ellipta) is the first ICS/LABA to launch with both an asthma and COPD indication at the same time.
Two strengths have been approved for the treatment of asthma (92/22 mcg and 184/22 mcg) and one strength has been approved for COPD (92/22 mcg).
All strengths are administered once-daily using the Ellipta, a new dry powder inhaler, according to manufacturer GlaxoSmithKline.
It said ease-of-use handling studies had shown that over 95% of asthma and COPD patients used the Ellipta inhaler device correctly for the first time.
The product is priced at £27.80 (92/22mcg) and £38.87 (184/22mcg).
Are you able to Speak out Safely?
Sign our petition to put pressure on your trust to support an open and transparent NHS